This result provides the rationale for novel therapeutic approaches against tumours with KRAS mutations and adds to recently reported combinatorial strategies for the treatment of KRAS-driven tumours involving MEK inhibitors (MEKi)50 or inhibitors targeting central kinases of mitotic progression, such as PLK1 (ref. 51). This evidence concerns the gene PLK1 and neoplasm.